BioPlus Acquisition Corp
BioPlus Acquisition Corp
BioPlus Acquisition Corp's leadership and board differentially consists of recognized industry leaders, including CEOs, CFOs, COOs, CSOs, Auditors, Investors, Bankers and experts covering all functional disciplines needed to maximize the value creation opportunity for a life sciences company. We bring over 200 years of collective experience in: 1) Identifying, developing and marketing value creating biotech assets, 2) Private and public company financing and dealmaking, 3) Audit and accounting, and 4) Advisory and board experience. We believe our team has demonstrated commitment to building valuable assets and can be leveraged as true long-term partners who can help maximize the value creation opportunity for a potential business combination.
Company Overview
Size
$230MM (over 5x oversubscribed)
$230MM (over 5x oversubscribed)
IPO Date
December 2, 2021
December 2, 2021
Unit Structure
1 Share of Class A Common Stock and 1/2 Warrant
1 Share of Class A Common Stock and 1/2 Warrant
Duration
18 months to acquire target
18 months to acquire target
Sector
Life Sciences
Life Sciences
Objectives
Acquire Biotech Company Valued Above $1B
Provide Operational Guidance and Mentorship for Partner Management Team Post Combination as a Public Company
Live Stock Chart
Team
Recent News
- 8-K Filing Pursuant to Full Exercise of Over-Allotment Optionon December 8, 2021
- BioPlus Acquisition Corp. Announces Pricing of Upsized $200,000,000 Initial Public Offeringon December 2, 2021
View All